Literature DB >> 16207590

Immune pathophysiology of aplastic anemia.

Shinji Nakao1, Xingmin Feng, Chiharu Sugimori.   

Abstract

Acquired aplastic anemia (AA) is considered an immune-mediated disease because approximately 70% of AA patients improve with immunosuppressive therapy. However, little is known about the inciting antigens or the mechanisms responsible for the destruction of hematopoietic stem cells by immune system attack. Recent advances in immunologic techniques have promoted our understanding of the pathogenesis of AA and have provided evidence that AA is an organ-specific T-cell-mediated disease localized in the bone marrow. Moreover, antibody screening of patients' serum with a complementary DNA library derived from hematopoietic cells has identified several proteins as candidate autoantigens in AA.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16207590     DOI: 10.1532/IJH97.05116

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  34 in total

1.  Relative increase of granulocytes with a paroxysmal nocturnal haemoglobinuria phenotype in aplastic anaemia patients: the high prevalence at diagnosis.

Authors:  H Wang; T Chuhjo; H Yamazaki; S Shiobara; M Teramura; H Mizoguchi; S Nakao
Journal:  Eur J Haematol       Date:  2001-03       Impact factor: 2.997

2.  Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals.

Authors:  D J Araten; K Nafa; K Pakdeesuwan; L Luzzatto
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

Review 3.  The pathophysiology of acquired aplastic anemia.

Authors:  N S Young; J Maciejewski
Journal:  N Engl J Med       Date:  1997-05-08       Impact factor: 91.245

4.  Interferon is a mediator of hematopoietic suppression in aplastic anemia in vitro and possibly in vivo.

Authors:  N C Zoumbos; P Gascon; J Y Djeu; N S Young
Journal:  Proc Natl Acad Sci U S A       Date:  1985-01       Impact factor: 11.205

5.  Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The German Aplastic Anemia Study Group.

Authors:  N Frickhofen; J P Kaltwasser; H Schrezenmeier; A Raghavachar; H G Vogt; F Herrmann; M Freund; P Meusers; A Salama; H Heimpel
Journal:  N Engl J Med       Date:  1991-05-09       Impact factor: 91.245

6.  HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome.

Authors:  Yogen Saunthararajah; Ryotaro Nakamura; Jun-Mo Nam; Jamie Robyn; Fausto Loberiza; Jaroslaw P Maciejewski; Toni Simonis; Jeffrey Molldrem; Neal S Young; A John Barrett
Journal:  Blood       Date:  2002-09-01       Impact factor: 22.113

7.  Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: improvement following anti-tumor necrosis factor-alpha antibody therapy.

Authors:  Helen A Papadaki; Heraklis D Kritikos; Vasilis Valatas; Dimitrios T Boumpas; George D Eliopoulos
Journal:  Blood       Date:  2002-07-15       Impact factor: 22.113

8.  Excessive production of tumor necrosis factor-alpha by bone marrow T lymphocytes is essential in causing bone marrow failure in patients with aplastic anemia.

Authors:  Takeshi Hara; Kazuki Ando; Hisashi Tsurumi; Hisataka Moriwaki
Journal:  Eur J Haematol       Date:  2004-07       Impact factor: 2.997

9.  Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria-type cells in bone marrow failure syndrome.

Authors:  Hongbo Wang; Tatsuya Chuhjo; Shizuka Yasue; Mitsuhiro Omine; Shinji Nakao
Journal:  Blood       Date:  2002-08-08       Impact factor: 22.113

10.  Diazepam-binding inhibitor-related protein 1: a candidate autoantigen in acquired aplastic anemia patients harboring a minor population of paroxysmal nocturnal hemoglobinuria-type cells.

Authors:  Xingmin Feng; Tatsuya Chuhjo; Chiharu Sugimori; Takeharu Kotani; Xuzhang Lu; Akiyoshi Takami; Hiroyuki Takamatsu; Hirohito Yamazaki; Shinji Nakao
Journal:  Blood       Date:  2004-06-24       Impact factor: 22.113

View more
  11 in total

1.  An animal model of chronic aplastic bone marrow failure following pesticide exposure in mice.

Authors:  Sumanta Chatterjee; Malay Chaklader; Pratima Basak; Prosun Das; Madhurima Das; Jacintha Archana Pereira; Ranjan Kumar Dutta; Samaresh Chaudhuri; Sujata Law
Journal:  Int J Stem Cells       Date:  2010-05       Impact factor: 2.500

Review 2.  Current concepts in the pathophysiology and treatment of aplastic anemia.

Authors:  Neal S Young; Rodrigo T Calado; Phillip Scheinberg
Journal:  Blood       Date:  2006-06-15       Impact factor: 22.113

Review 3.  Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer.

Authors:  Iosune Baraibar; Ignacio Melero; Mariano Ponz-Sarvise; Eduardo Castanon
Journal:  Drug Saf       Date:  2019-02       Impact factor: 5.606

Review 4.  Aplastic anemia is related to alterations in T cell receptor signaling.

Authors:  Yankai Xiao; Suwen Zhao; Bo Li
Journal:  Stem Cell Investig       Date:  2017-10-24

Review 5.  Acyl-coenzyme A binding domain containing 3 (ACBD3; PAP7; GCP60): an emerging signaling molecule.

Authors:  Jinjiang Fan; Jun Liu; Martine Culty; Vassilios Papadopoulos
Journal:  Prog Lipid Res       Date:  2010-01-04       Impact factor: 16.195

6.  Aplastic Anemia in a Patient with Cronkhite-Canada Syndrome.

Authors:  Keisuke Kidoguchi; Yasushi Kubota; Shun Fujimoto; Yasuhisa Sakata; Haruna Kizuka-Sano; Kyosuke Yamaguchi; Hiroshi Ureshino; Hiroo Katsuya; Toshihiko Ando; Motohiro Esaki; Shinya Kimura
Journal:  Intern Med       Date:  2021-05-15       Impact factor: 1.271

7.  Human Acquired Aplastic Anemia Patients' Bone-Marrow-Derived Mesenchymal Stem Cells Are Not Influenced by Hematopoietic Compartment and Maintain Stemness and Immune Properties.

Authors:  Vandana Sharma; Sonali Rawat; Suchi Gupta; Sweta Tamta; Rinkey Sharma; Tulika Seth; Sujata Mohanty
Journal:  Anemia       Date:  2021-04-29

8.  Dysregulated miR34a/diacylglycerol kinase ζ interaction enhances T-cell activation in acquired aplastic anemia.

Authors:  Yuan-Xin Sun; Hui Li; Qi Feng; Xin Li; Ying-Yi Yu; Li-Wei Zhou; Yan Gao; Guo-Sheng Li; Juan Ren; Chun-Hong Ma; Cheng-Jiang Gao; Jun Peng
Journal:  Oncotarget       Date:  2017-01-24

9.  Aplastic anemia secondary to nivolumab and ipilimumab in a patient with metastatic melanoma: a case report.

Authors:  D E Meyers; W F Hill; A Suo; V Jimenez-Zepeda; T Cheng; N A Nixon
Journal:  Exp Hematol Oncol       Date:  2018-03-20

10.  T-cell expression of Bruton's tyrosine kinase promotes autoreactive T-cell activation and exacerbates aplastic anemia.

Authors:  Simo Xia; Xiang Liu; Xuetao Cao; Sheng Xu
Journal:  Cell Mol Immunol       Date:  2019-08-20       Impact factor: 11.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.